Construct for introducing foreign substances and its use

Abstract

To provide a technique for efficiently introducing a target foreign substance from the outside of a eukaryotic cell into at least the cytoplasm of the cell.SOLUTION: Disclosed is a method for introducing a foreign substance of interest from outside a eukaryotic cell into at least the cytoplasm of the cell in vitro. The method comprises (1) preparing a foreign substance introduction construct having a carrier peptide fragment consisting of either an amino acid sequence: KKRTLRKSNRKKRWPC (SEQ ID NO: 1) or KKRTLRKKKRKKRWPC (SEQ ID NO: 2) and the foreign substance of interest coupled to a N-terminus and / or C-terminus of the carrier peptide fragment; (2) supplying the foreign substance introduction construct into a sample containing target eukaryotic cells; and (3) incubating the sample supplied with the foreign substance introduction construct and introducing the construct into the eukaryotic cell in the sample.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to a method for introducing (transporting) a foreign substance from the outside of a eukaryotic cell to the inside of the cell, and a construct for introducing a foreign substance to be used in the method. [Background technology]

[0002] Conventionally, foreign substances such as polypeptides, particularly physiologically active substances, have been introduced into cells (eukaryotic cells) of humans and other mammals to transform the characteristics of the cells (and even the tissues and organs made up of those cells) or to improve or enhance the functions of those cells.

[0003] For example, Patent Document 1 discloses a construct for introducing a foreign substance, which contains a foreign substance of interest and the amino acid sequence (carrier peptide fragment) set forth in SEQ ID NO: 3, known as the nucleolar localization signal (hereinafter referred to as "NoLS") described in Non-Patent Document 1. This construct can pass through the cell membrane of a eukaryotic cell with high efficiency, and therefore can introduce the foreign substance of interest from the outside of the eukaryotic cell into the cytoplasm of the cell with high efficiency.

[0004] Furthermore, Non-Patent Document 2 discloses a technique for predicting cell membrane-permeable peptides consisting of short amino acid sequences (approximately 20 residues or less) with low arginine content and reduced toxicity using deep learning technology. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] International Publication No. 2011 / 013700 [Non-patent literature]

[0006] [Non-Patent Document 1] JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 281, No. 35, 2006, pp. 25223-25230 [Non-patent document 2] AN OPEN ACCESS JOURNAL OF THE AMERICAN CHEMICAL SOCIETY Au, Vol. 1, No. 11, 2021, pp. 2009-2020 Summary of the Invention [Problem to be solved by the invention]

[0007] In recent years, cell membrane-permeable peptides have been of increasing interest from the perspective of medical treatment, and there is a demand for the development of techniques for more efficiently introducing foreign substances into target cells.

[0008] The present invention was created to address such needs, and aims to provide a method for efficiently introducing a foreign substance of interest into at least the cytoplasm of a eukaryotic cell from the outside of the cell, and a construct for introducing a foreign substance that can efficiently introduce a foreign substance of interest into at least the cytoplasm of the cell from the outside of the cell. [Means for solving the problem]

[0009] The present inventors have found that mutants (e.g., SEQ ID NOS: 4 and 5) in which the asparagine at position 8 and the aspartic acid at position 9, counting from the N-terminus of the amino acid sequence shown in SEQ ID NO: 3, are substituted with other amino acids have high cell membrane permeability, in order to more efficiently introduce the exogenous substance introduction construct disclosed in the above-mentioned Patent Document 1 from the outside of the eukaryotic cell into the cytoplasm of the cell. Furthermore, the present inventors have conducted extensive studies to improve the cell membrane permeability of such mutants, and have found that cell membrane permeability can be further improved by adding tryptophan-proline-cysteine ​​(WPC), which does not contain arginine or lysine, which are generally suggested to contribute to cell membrane permeability, to the C-terminus of such mutants.

[0010] The method disclosed herein is a method for introducing a foreign substance of interest into at least the cytoplasm of a eukaryotic cell from the outside of the cell in vitro, comprising the steps of: (1) the following amino acid sequence: KKRTLRKSNRKKRWPC (SEQ ID NO: 1); KKRTLRKKKRKKRWPC (SEQ ID NO: 2); a carrier peptide fragment consisting of any one of the foreign substance of interest bound to the N-terminus and / or C-terminus of the carrier peptide fragment; providing a construct for introducing an exogenous substance, (2) providing the construct for introducing a foreign substance into a sample containing a target eukaryotic cell; (3) incubating the sample to which the construct for introducing a foreign substance has been supplied to introduce the construct into eukaryotic cells in the sample; Includes. Here, "foreign substance" refers to inorganic and organic compounds that can be bound directly or indirectly via an appropriate linker to the N-terminus or C-terminus of the carrier peptide fragment, and that have a molecular size and chemical properties that allow them to be introduced into eukaryotic cells.

[0011] According to the method of the above configuration, the carrier peptide fragment contained in the construct for introducing foreign substances has high cell membrane permeability, so that the foreign substance of interest can be efficiently introduced from the outside of the eukaryotic cell (outside the cell membrane) through the cell membrane into the cytoplasm (preferably further through the nuclear membrane into the nucleus).

[0012] In a preferred embodiment of the method disclosed herein, the foreign substance is any organic compound selected from the group consisting of polypeptides, nucleic acids, dyes, and drugs. Here, "polypeptide" refers to a polymer having a structure in which multiple amino acids are linked by peptide bonds. Polypeptides are not limited by the number of peptide bonds (i.e., the number of amino acid residues). That is, polypeptides include those generally called peptides, which have from 10 to less than 300 amino acid residues, and those generally called proteins (polymeric compounds typically consisting of 300 or more amino acid residues). In the art, there is no strict distinction between polypeptides and proteins. In this specification, polymers (including oligomers) consisting of multiple amino acid residues are collectively referred to as polypeptides. Furthermore, "nucleic acid" refers to a polymer of nucleotides, and includes DNA and RNA. "Nucleic acid" is not limited by the number of bases.

[0013] In a preferred embodiment of the method disclosed herein, the foreign substance is located on the C-terminal side of the carrier peptide fragment. According to this configuration, a foreign substance of interest can be efficiently introduced into at least the cytoplasm of a eukaryotic cell from the outside of the cell.

[0014] In a preferred embodiment of the method disclosed herein, the α-amino group of the lysine at the N-terminus of the carrier peptide fragment is acetylated, which can improve the intracellular stability of the construct.

[0015] In a preferred embodiment of the method disclosed herein, the eukaryotic cells into which the construct for introducing a foreign substance is introduced are cells of a human or non-human mammal. The methods disclosed herein allow for efficient introduction of foreign substances into the cytoplasm of human or non-human mammalian cells.

[0016] Furthermore, in order to achieve the above-mentioned objectives, the present disclosure provides an artificially constructed construct for introducing (transporting) a target foreign substance from the outside (i.e., outside the cell membrane) of a eukaryotic cell (particularly various animal cells such as humans and other mammals that do not have a cell wall) into at least the cytoplasm (preferably further into the nucleus) of the cell. That is, the construct for introducing a foreign substance disclosed herein has the following amino acid sequence: KKRTLRKSNRKKRWPC (SEQ ID NO: 1); KKRTLRKKKRKKRWPC (SEQ ID NO: 2); and the foreign substance of interest bound to the N-terminus and / or C-terminus of the carrier peptide fragment. Such constructs have high cell membrane permeability, and therefore can efficiently introduce foreign substances of interest into target eukaryotic cells.

[0017] In a preferred embodiment of the construct for introducing an exogenous substance disclosed herein, the exogenous substance is any organic compound selected from the group consisting of polypeptides, nucleic acids, dyes, and drugs.

[0018] In a preferred embodiment of the construct for introducing an exogenous substance disclosed herein, the exogenous substance is located at the C-terminus of the carrier peptide fragment. In a preferred embodiment of the construct for introducing an exogenous substance disclosed herein, the α-amino group of the lysine at the N-terminus of the carrier peptide fragment is acetylated. [Brief explanation of the drawings]

[0019] [Figure 1]1 is a graph showing MFI values ​​obtained by adding the constructs (additives) shown in Examples 1 to 5 to a culture medium of HeLa cells, culturing the cells, and then analyzing the cells with a flow cytometer. DETAILED DESCRIPTION OF THE INVENTION

[0020] Preferred embodiments of the present technology are described below. Matters other than those specifically mentioned in this specification that are necessary for implementation (for example, general matters such as methods for chemically synthesizing peptides, cell culture techniques, and preparation of compositions containing peptides or nucleic acids as components) can be understood as matters of design by those skilled in the art based on conventional techniques in the fields of cell engineering, physiology, medicine, pharmacology, organic chemistry, biochemistry, genetic engineering, protein engineering, molecular biology, genetics, etc. Furthermore, this technology can be implemented based on the contents disclosed in this specification and the common general technical knowledge in the field. In the following explanation, amino acids are sometimes represented by one-letter symbols in accordance with the nomenclature for amino acids set forth in the IUPAC-IUB guidelines (however, in the sequence listing, they are represented by three-letter symbols). In this specification, the term "amino acid residue" includes the N-terminal amino acid and the C-terminal amino acid of a peptide chain, unless otherwise specified.

[0021] Furthermore, as used herein, the term "synthetic peptide" refers to a peptide fragment whose peptide chain does not exist independently and stably in nature, but is produced by artificial chemical synthesis or biosynthesis (i.e., production based on genetic engineering) and can exist stably in a given composition. Here, the term "peptide" refers to an amino acid polymer having multiple peptide bonds and is not limited by the number of amino acid residues. In the amino acid sequences described herein, the left side always represents the N-terminus and the right side represents the C-terminus.

[0022] The construct for introducing an exogenous substance disclosed herein has the following amino acid sequence: KKRTLRKSNRKKRWPC (SEQ ID NO: 1); KKRTLRKKKRKKRWPC (SEQ ID NO: 2); and the foreign substance of interest bound to the N-terminus and / or C-terminus of the carrier peptide fragment. The above-mentioned carrier peptide fragment is a peptide defined (understood) by the amino acid sequence shown in SEQ ID NO: 1 or 2, and can confer cell membrane permeability (more preferably nuclear transport ability (nuclear membrane permeability)) to the construct in eukaryotic cells.

[0023] The amino acid sequence shown in SEQ ID NO: 1 is a sequence in which tryptophan-proline-cysteine ​​(WPC) is added to the C-terminus of the amino acid sequence shown in SEQ ID NO: 4. The peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 has higher cell membrane permeability than the peptide consisting of the amino acid sequence shown in SEQ ID NO: 4.

[0024] The peptide consisting of the amino acid sequence shown in SEQ ID NO: 4 is a variant of the peptide consisting of the amino acid sequence shown in SEQ ID NO: 3, which has been reported to have cell membrane permeability. Specifically, the 8th amino acid residue (asparagine residue) of the amino acid sequence of SEQ ID NO: 3 is substituted with a serine residue, and the 9th amino acid residue (aspartic acid residue) is substituted with an asparagine residue. The peptide consisting of the amino acid sequence shown in SEQ ID NO: 4 has higher cell membrane permeability than the peptide consisting of the amino acid sequence shown in SEQ ID NO: 3, and was discovered by the present inventors. The amino acid sequence shown in SEQ ID NO: 3 is a NoLS corresponding to a sequence portion (motif) consisting of a total of 13 amino acid residues from the 491st to the 503rd amino acid residues of LIM kinase 2 (see Non-Patent Document 1), a protein kinase involved in intracellular signal transduction present in human endothelial cells. In other words, the degree of cell membrane permeability can be in the order of SEQ ID NO: 3 < SEQ ID NO: 4 < SEQ ID NO: 1.

[0025] The amino acid sequence shown in SEQ ID NO: 2 is a sequence in which tryptophan-proline-cysteine ​​(WPC) is added to the C-terminus of the amino acid sequence shown in SEQ ID NO: 5. The peptide consisting of the amino acid sequence shown in SEQ ID NO: 2 has higher cell membrane permeability than the peptide consisting of the amino acid sequence shown in SEQ ID NO: 5.

[0026] The peptide consisting of the amino acid sequence shown in SEQ ID NO: 5 is a variant of the peptide consisting of the amino acid sequence shown in SEQ ID NO: 3. Specifically, the eighth amino acid residue (asparagine residue) and the ninth amino acid residue (aspartic acid residue) of the amino acid sequence shown in SEQ ID NO: 3 are both substituted with lysine residues. The peptide consisting of the amino acid sequence shown in SEQ ID NO: 5 has higher cell membrane permeability than the peptide consisting of the amino acid sequence shown in SEQ ID NO: 3, and this was discovered by the present inventors. That is, the degree of cell membrane permeability can be SEQ ID NO: 3 < SEQ ID NO: 5 < SEQ ID NO: 2. Furthermore, since the peptide consisting of the amino acid sequence shown in SEQ ID NO: 5 has excellent nucleolar transportability, the amino acid sequence shown in SEQ ID NO: 2, which includes the amino acid sequence shown in SEQ ID NO: 5, can be used as a nucleolar marker.

[0027] Although the detailed mechanism is unknown, cell membrane permeability can be improved by adding the amino acid sequence: WPC to the C-terminus of NoLS (SEQ ID NO: 3) of LIM kinase 2, which exhibits cell membrane permeability, or a mutant thereof. Therefore, the amino acid sequence constituting the carrier peptide fragment of the construct for introducing a foreign substance disclosed herein further contains the following amino acid sequence: KKRTLRKNDRKKRWPC (SEQ ID NO: 6); KKRTLRKKRRKKRWPC (SEQ ID NO: 7); KKRTLRKRKRKKRWPC (SEQ ID NO: 8); KKRTLRKRRRKKRWPC (SEQ ID NO: 9); The amino acid sequences shown in SEQ ID NOs: 7 to 9 are amino acid sequences in which the amino acid sequence WPC has been added to the C-terminus of a NoLS mutant of LIM kinase 2, which has been discovered by the present inventors to have excellent cell membrane permeability. The amino acid sequences shown in SEQ ID NOs: 7 to 9 have excellent nucleolar transportability and can therefore be used as nucleolar markers.

[0028] The "carrier peptide fragment" disclosed herein typically has the same amino acid sequence as the above-mentioned amino acid sequence, but also includes modified sequences of such amino acid sequences as long as cell membrane permeability is not impaired. Here, a "modified sequence" refers to an amino acid sequence (modified amino acid sequence) formed by substituting, deleting, and / or adding (inserting) one or several (typically two or three) amino acid residues. Such slightly modified sequences can be easily utilized by those skilled in the art based on the information disclosed herein, and are therefore encompassed by the "carrier peptide fragment" as a technical concept disclosed herein. Typical examples of modified sequences herein include sequences resulting from conservative substitution of one, two, or three amino acid residues (so-called conservative amino acid replacement), and sequences in which one, two, or three amino acid residues are added (inserted) or deleted from a given amino acid sequence. Typical examples of conservative substitutions include sequences in which a basic amino acid residue is substituted with another basic amino acid residue (e.g., mutual substitution of a lysine residue with an arginine residue), and sequences in which a hydrophobic amino acid residue is substituted with another hydrophobic amino acid residue (e.g., mutual substitution of a leucine residue, an isoleucine residue, and a valine residue).

[0029] A construct for introducing a foreign substance can be designed and constructed by binding (linking) the desired foreign substance directly or indirectly via a suitable linker to the N-terminus and / or C-terminus of the above-mentioned carrier fragment. The linker is not particularly limited, but may be a peptidic linker or a non-peptidic linker. It is preferable, but not particularly limited, that the amino acid sequence constituting the peptidic linker is one that does not cause steric hindrance and is flexible. The peptidic linker may be, for example, a linker consisting of 10 or less amino acid residues (more preferably 1 to 5, e.g., 1, 2, 3, 4, or 5 amino acid residues) containing one or more amino acid residues selected from glycine, alanine, serine, etc. Furthermore, β-alanine may be used as such a linker. The non-peptidic linker is not particularly limited, but may be, for example, an alkyl linker, a PEG (polyethylene glycol) linker, an aminohexanoyl spacer, or the like.

[0030] The foreign substance is typically an organic compound such as a polypeptide, nucleic acid, dye, or drug. The foreign substance may be, for example, a polypeptide. When the foreign substance is a polypeptide, a peptide chain containing the amino acid sequence constituting the polypeptide and the amino acid sequence constituting the carrier peptide fragment can be designed and biosynthesized or chemically synthesized to produce a desired construct for introducing a foreign substance. Alternatively, a construct for introducing a foreign substance can be constructed by directly or indirectly linking various nucleic acids such as DNA or RNA, dyes (e.g., various fluorescent dye compounds such as FAM and FITC), or organic compounds that function as drugs (e.g., antitumor agents including nucleic acid-based antitumor agents such as 5-fluorouracil (5FU) and antiviral agents such as azidothymidine (AZT)) to the N-terminus and / or C-terminus of the carrier peptide fragment described above using various scientific techniques known in the art. Although not particularly limited, the function of the foreign substance may be, for example, promoting stem cell differentiation induction (stem cell differentiation induction activity), inhibiting tumor cell proliferation (antitumor activity), inhibiting the proliferation of virus-infected cells (antiviral activity), etc.

[0031] In a construct for introducing an exogenous substance, the number of exogenous substances bound to a carrier peptide fragment is not particularly limited. That is, one or more exogenous substances may be bound to one carrier peptide fragment. Although not particularly limited, for example, a polypeptide, nucleic acid, drug, etc. may be bound to the C-terminus of one carrier peptide fragment, and a dye may be bound to the N-terminus. Binding a dye to a carrier peptide fragment is preferred because it facilitates evaluation of the efficiency of introduction of an exogenous substance into eukaryotic cells and its intracellular localization.

[0032] When the foreign substance is a polypeptide, the polypeptide (amino acid sequence) to be used is not particularly limited. For example, a foreign substance may be a polypeptide or protein having a relatively large number of amino acid residues, such as about 100 to 1000 amino acid residues. Typically, the total number of amino acid residues constituting a synthetic peptide prepared as a construct for introducing a foreign substance is several to several tens (e.g., 10 or more), and is suitably 1000 or less, preferably 600 or less, more preferably 500 or less, and particularly preferably 300 or less (e.g., 10 to 300). Polypeptides of such lengths are easy to synthesize (biosynthesize or chemically synthesize) and are easy to use.

[0033] Preferred foreign substances are mature or precursor (including pro- and prepro-) forms of polypeptides involved in functions such as the development, differentiation, proliferation, canceration, homeostasis, and metabolic regulation of various cells and tissues (organs). Furthermore, the method for introducing foreign substances disclosed herein can also be carried out to introduce into cells a polypeptide whose function has not previously been known, in order to elucidate the function of the polypeptide within the cell (in a living tissue). For example, when the eukaryotic cells to be introduced with a foreign substance are human or other mammalian stem cells, it is preferable to use mature forms or precursors of polypeptides with various physiological activities involved in inducing the differentiation of the stem cells. Note that "stem cells" encompass somatic stem cells, embryonic stem cells, and induced pluripotent stem cells (hereinafter referred to as iPS cells). Furthermore, when the eukaryotic cells to be introduced with a foreign substance are cancer cells (tumor cells), it is preferable to use various polypeptides involved in inducing apoptosis of the cancer cells (tumor cells). Alternatively, in this case, it is preferable to use polypeptides that can inhibit the suppression of the immune surveillance mechanism of cancer cells (tumor cells). Furthermore, when the eukaryotic cells to be introduced with a foreign substance are bacterially or virally infected cells, it is preferable to use various polypeptides involved in inducing apoptosis of the infected cells, polypeptides that can inhibit bacterial or viral proliferation in the infected cells, or polypeptides that can inhibit the spread of bacterial or viral infection from the infected cells. As with carrier peptide fragments, the polypeptide as a foreign substance may contain a modified amino acid sequence formed by substitution, deletion, and / or addition (insertion) of one or several amino acid residues, as long as it retains its function.

[0034] In constructs for foreign substance delivery in which a foreign substance is bound to the C-terminus of a carrier peptide fragment, it is preferable that the α-amino group of the N-terminal lysine of the carrier peptide fragment be acetylated. Although the detailed mechanism is unknown, the α-amino group of the N-terminal amino acid of many proteins in eukaryotic cells is acetylated, and such a configuration can improve the intracellular stability of the construct.

[0035] The C-terminal amino acid residue of the construct for introducing a foreign substance is preferably amidated. Amidation of the carboxyl group of an amino acid residue (typically the C-terminal amino acid residue of a peptide chain) can improve the structural stability (e.g., protease resistance) of the construct in the cytoplasm and nucleolus. Furthermore, amidation of the carboxyl group improves the hydrophilicity of the construct, thereby improving the solubility of the construct in aqueous solvents. Examples of such aqueous solvents include water, various buffer solutions, physiological saline (e.g., PBS), and cell culture medium. For example, in the case of a construct for introducing a foreign substance in which the foreign substance is bound to the N-terminus of a carrier peptide fragment, it is preferable that the carboxyl group of the C-terminal cysteine ​​of the carrier peptide fragment is amidated.Furthermore, for example, when the foreign substance is a polypeptide and such polypeptide is bound to the C-terminus of the carrier peptide fragment, it is preferable that the carboxyl group of the C-terminal amino acid residue of the polypeptide is amidated.

[0036] Constructs for introducing foreign substances, including polypeptides constituting the foreign substance, carrier peptide fragments, and peptidic linkers, that have relatively short peptide chains can be easily produced using standard chemical synthesis methods. For example, either conventional solid-phase or liquid-phase synthesis methods may be employed. Solid-phase synthesis using Boc (t-butyloxycarbonyl) or Fmoc (9-fluorenylmethoxycarbonyl) as the amino-protecting group is preferred. Specifically, the above-described peptide chains having the desired amino acid sequence and modifications (e.g., N-terminal acetylation, C-terminal amidation) can be synthesized by solid-phase synthesis using a commercially available peptide synthesizer. Furthermore, only a portion of the peptide chain may be synthesized using the above method; for example, a peptide chain containing only the carrier peptide fragment, or a carrier peptide fragment and a peptidic linker, may be synthesized.

[0037] Alternatively, the peptide portion may be biosynthesized using genetic engineering techniques. That is, a polynucleotide (typically DNA) with a nucleotide sequence (including an ATG initiation codon) encoding the desired amino acid sequence is synthesized. Then, a recombinant vector containing an expression gene construct consisting of the synthesized polynucleotide (DNA) and various regulatory elements (including promoters, ribosome binding sites, terminators, enhancers, and various cis-elements that control expression levels) for expressing the amino acid sequence in host cells is constructed according to the host cell. This recombinant vector is introduced into a specific host cell (e.g., yeast, insect cell, or plant cell) using standard techniques, and the host cell or a tissue or individual containing the cell is cultured under specific conditions. This allows the target peptide to be produced intracellularly. The target peptide portion can then be isolated from the host cell (or from the culture medium if secreted), and, if necessary, refolded, purified, or the like, to obtain the target peptide portion. The method for constructing a recombinant vector and the method for introducing the constructed recombinant vector into a host cell may be any method conventionally used in the relevant field, and such methods themselves do not particularly characterize the present technology, so detailed explanations thereof will be omitted.

[0038] For example, a fusion protein expression system can be used to efficiently mass-produce the polypeptide in a host cell. Specifically, a gene (DNA) encoding the amino acid sequence of the polypeptide of interest is chemically synthesized, and the synthetic gene is introduced into a suitable site of a suitable fusion protein expression vector (e.g., a GST (Glutathione S-transferase) fusion protein expression vector such as the pET series from Novagen and the pGEX series from Amersham Biosciences). Then, a host cell (typically Escherichia coli) is transformed with the vector. The resulting transformant is cultured to prepare the fusion protein of interest. The protein is then extracted and purified. The purified fusion protein is then cleaved with a specific enzyme (protease) to release the peptide fragment of interest (i.e., the nucleotide sequence of the target polypeptide). The resulting construct (i.e., the designed artificial polypeptide) is recovered by a method such as affinity chromatography. By using such a conventionally known fusion protein expression system (for example, the GST / His system provided by Amersham Biosciences), the desired foreign substance introduction construct (artificial polypeptide) can be produced. Alternatively, a template DNA for a cell-free protein synthesis system (i.e., a synthetic gene fragment containing a nucleotide sequence encoding the amino acid sequence of the peptide portion of the construct for introducing a foreign substance) can be constructed, and various compounds (ATP, RNA polymerase, amino acids, etc.) necessary for synthesizing the peptide portion can be used to employ a so-called cell-free protein synthesis system to synthesize the desired polypeptide in vitro. Regarding cell-free protein synthesis systems, for example, Shimizu et al. (Shimizu et al., Nature Biotechnology, 19, 751-755 (2001)) and Madin et al. (Madin et al., Proc. Natl. Acad. Sci. USA, 97(2), 559-564 (2000)) are useful references. Based on the techniques described in these papers, many companies were already contracted to produce polypeptides at the time of filing the present application, and cell-free protein synthesis kits (available, for example, from CellFree Science Co., Ltd. in Japan) were commercially available.

[0039] Single-stranded or double-stranded polynucleotides containing a nucleotide sequence encoding the peptide portion of a construct for introducing an exogenous substance and / or a nucleotide sequence complementary to said sequence can be easily produced (synthesized) by conventional methods. Specifically, by selecting codons corresponding to each amino acid residue constituting a designed amino acid sequence, the nucleotide sequence corresponding to said amino acid sequence can be easily determined and provided. Once the nucleotide sequence is determined, a polynucleotide (single-stranded) corresponding to the desired nucleotide sequence can be easily obtained using a DNA synthesizer or the like. Furthermore, the obtained single-stranded DNA can be used as a template to obtain the desired double-stranded DNA by various enzymatic synthesis methods (typically PCR). Furthermore, the polynucleotide may be in the form of DNA or RNA (e.g., mRNA). DNA can be provided as either double-stranded or single-stranded. When provided as a single-stranded DNA, it may be the coding strand (sense strand) or the non-coding strand (antisense strand) of a complementary sequence. The polynucleotides thus obtained can be used as materials for constructing recombinant genes (expression cassettes) for peptide production in various host cells or in cell-free protein synthesis systems, as described above.

[0040] The construct for introducing an exogenous substance can be suitably used as an active ingredient in a composition for use based on the function of the exogenous substance. The construct for introducing an exogenous substance may be in the form of a salt, as long as the function of the exogenous substance is not lost. For example, an acid addition salt obtainable by addition reaction of a commonly used inorganic or organic acid according to standard methods can be used. Therefore, the "construct for introducing an exogenous substance" described in this specification and claims encompasses such salt forms.

[0041] The construct for introducing an exogenous substance can be provided as a composition that can contain, in addition to the construct for introducing an exogenous substance as an active ingredient, various medicamentally (pharmacologically) acceptable carriers depending on the form of use. The carrier is preferably one that is commonly used in peptide drugs as a diluent, excipient, or the like. While such a carrier may vary depending on the application and form of the exogenous substance introduction construct, typical examples include water, physiological buffer solutions, and various organic solvents. Furthermore, such a carrier may be an aqueous solution of an appropriate concentration of alcohol (e.g., ethanol), glycerol, a non-drying oil such as olive oil, or a liposome. Secondary components that may be contained in the pharmaceutical composition include various fillers, extenders, binders, humectants, surfactants, dyes, fragrances, and the like.

[0042] The form of the composition is not particularly limited. For example, typical forms include solutions, suspensions, emulsions, aerosols, foams, granules, powders, tablets, capsules, and ointments. Furthermore, for use in injections, etc., the composition may be in the form of a freeze-dried product or granulated product that can be dissolved in physiological saline or an appropriate buffer solution (e.g., PBS) immediately before use to prepare a medicinal solution. The process of preparing various forms of drugs (compositions) using a construct for introducing a foreign substance (main component) and various carriers (secondary components) may be in accordance with conventionally known methods, and since such formulation methods themselves do not characterize the present technology, detailed explanations will be omitted. For example, Comprehensive Medicinal Chemistry, edited by Corwin Hansch, published by Pergamon Press (1990), is an example of a source of detailed information on formulations.

[0043] The present disclosure provides a method for introducing a construct for introducing a foreign substance into a living body (in vivo) or a living body (in vitro) using the construct (composition) for introducing a foreign substance disclosed herein. The method roughly comprises the following steps (1) to (3): (1) preparing a construct for introducing a foreign substance, the construct comprising a carrier peptide fragment consisting of either the amino acid sequence shown in SEQ ID NO: 1 or 2, and the foreign substance of interest bound to the N-terminus and / or C-terminus of the carrier peptide fragment; (2) providing a construct for introducing a foreign substance into a sample containing a target eukaryotic cell; (3) incubating the sample supplied with the construct for introducing a foreign substance to introduce the construct into eukaryotic cells in the sample.

[0044] The "eukaryotic cells" mentioned above include, for example, various tissues, organs, blood, lymph, etc. in vivo. The "eukaryotic cells" mentioned above include, for example, various cell masses, tissues, organs, blood, lymph, and cell lines extracted from a living body in vitro.

[0045] The compositions containing the constructs disclosed herein can be used in vivo in a manner and dosage appropriate for their form and purpose. For example, as a liquid formulation, they can be administered in a desired amount to the affected area (e.g., malignant tumor tissue, virus-infected tissue, inflammatory tissue, etc.) of a patient (i.e., living organism) by intravenous, intramuscular, subcutaneous, intradermal, or intraperitoneal injection. Alternatively, solid forms such as tablets, or gels or aqueous jelly forms such as ointments, can be administered directly to the affected area (e.g., affected areas such as tissues or organs containing tumor cells, virus-infected cells, inflammatory cells, etc.). Alternatively, solid forms such as tablets can be administered orally. For oral administration, encapsulation or application of a protective (coating) material is preferred to prevent degradation by digestive enzymes in the digestive tract.

[0046] Alternatively, an appropriate amount of the composition disclosed herein (i.e., an appropriate amount of the construct for introducing an exogenous substance) may be added at least once to the culture medium of eukaryotic cells being cultured in vitro. The amount and frequency of addition per addition are not particularly limited, as they may vary depending on the type of eukaryotic cells being cultured, cell density (cell density at the start of culture), number of passages, culture conditions, type of medium, and other conditions. For example, it is preferable to add the carrier peptide fragment once, twice, or more times so that the concentration of the carrier peptide fragment in the culture medium is approximately in the range of 0.05 μM to 100 μM, e.g., 0.5 μM to 50 μM, or e.g., 1 μM to 20 μM. The incubation time after addition of the construct is also not particularly limited, as it may vary depending on the type of eukaryotic cells and various conditions. For example, it may be 0.5 hours or more, 1 hour or more, 4 hours or more, 8 hours or more, or 20 hours or more. The incubation conditions are not particularly limited as they may differ depending on the type of eukaryotic cell, but for example, the cells can be incubated in a 5% CO 2 atmosphere at 37°C. An example of an in vitro introduction method is shown in the Examples below.

[0047] The method for evaluating the efficiency of introduction of a construct for introducing a foreign substance is not particularly limited. For example, when a dye (typically a fluorescent dye compound) is bound to the construct, the efficiency of introduction into eukaryotic cells can be evaluated using microscopic observation (e.g., fluorescence microscopic observation) or flow cytometry. The efficiency of introduction of the construct can also be evaluated by immunochemical techniques (e.g., Western blotting, immunocytostaining, etc.) using an antibody that specifically recognizes the peptide portion of the construct.

[0048] Hereinafter, several examples of the present technology will be described, but it is not intended that the present invention be limited to those shown in these examples.

[0049] <Preparation of constructs for introducing foreign substances> Synthetic peptides (peptides 1 to 4) with the amino acid sequences shown in Table 1 were prepared. Peptides 1 to 4 were all synthesized by solid-phase synthesis (Fmoc method) using a commercially available peptide synthesizer according to the manual. Furthermore, the α-amino group of the lysine residue at the N-terminus of peptides 1 to 4 was all acetylated. Furthermore, peptide 3 was synthesized by amidating the carboxyl group of the arginine residue at the C-terminus (peptide 3'). It should be noted that the manner of use of the peptide synthesizer itself does not characterize the technology disclosed herein, and therefore a detailed description thereof will be omitted.

[0050] [Table 1]

[0051] Next, the C-terminal amino acid residues of peptides 1 to 4 (excluding peptide 3') were ligated with a fluorescent dye, FAM (C 21 H 12O7:5(6)-Carboxyfluorescein (molecular weight 376.3, excitation wavelength 495 nm, fluorescence wavelength 520 nm) was directly coupled to the peptide 1 using a standard method. This resulted in the construction for introducing a foreign substance containing peptide 1 (also referred to as "Sample 1"), the construction for introducing a foreign substance containing peptide 2 (also referred to as "Sample 2"), the construction for introducing a foreign substance containing peptide 3 (also referred to as "Sample 3"), and the construction for introducing a foreign substance containing peptide 4 (also referred to as "Sample 4"). Furthermore, FAM was directly coupled to the N-terminus of peptide 3' using a standard method to obtain the construction for introducing a foreign substance containing peptide 3' (also referred to as "Sample 3'"). Samples 1 to 4 were each diluted with dimethyl sulfoxide (DMSO) to prepare sample solutions 1 to 4 with a sample concentration of 2 mM.

[0052] <Evaluation of cell membrane permeability by flow cytometry> HeLa cells (an established cell line derived from human cervical cancer cells) were used as eukaryotic cells to analyze the cell membrane permeability of peptides 1 to 4. In this test, as shown in Table 2, Samples 1 to 4 prepared above were used in Examples 1 to 4, respectively, and FAM solution was used in Example 5.

[0053] [Table 2]

[0054] (Example 1) HeLa cells were cultured in a common culture medium, Dulbecco's modified Eagle's medium (DMEM) (Fujifilm Wako Pure Chemical Industries, Ltd., Cat No. 043-30085) containing 10% FBS (fetal bovine serum). After washing the HeLa cells attached to the culture plate with PBS, a 0.25% trypsin / EDTA solution was added and incubated at 37°C for 3 minutes. After this incubation, the above-mentioned 10% FBS-containing DMEM was added to inactivate the trypsin, and the cells were precipitated by centrifugation at 150 × g for 5 minutes. After removing the supernatant resulting from centrifugation, the above-mentioned 10% FBS-containing DMEM was added to the precipitate (cell pellet), and approximately 2 × 10 5 A cell suspension of 100 cells / mL was prepared. 1 mL of the cell suspension was added to each well of a commercially available 6-well plate (AGC Technoglass Co., Ltd.), and the cells were seeded (approximately 2 × 10 5 cells / well). The 2 mM sample solution 1 was diluted with the 10% FBS-containing DMEM to prepare a sample solution 1 with a sample 1 concentration of 20 μM. Then, 1 mL of the 20 μM sample solution 1 was added to the well (i.e., the sample 1 concentration in the culture medium in the well was 10 μM, and the DMSO concentration was 0.5%). The cells were then incubated at 37°C under 5% CO2 for 20 hours.

[0055] After 20 hours of incubation, the culture supernatant was removed from the wells, and the cells in the wells were washed twice with 1 mL of PBS. Next, 200 μL of 0.25% trypsin / EDTA solution was added to the wells, and the wells were incubated at 37°C for 3 minutes. After the incubation, 400 μL of the above-mentioned 10% FBS-containing DMEM was added to the wells to inactivate the trypsin, and the cell suspension in the wells was transferred to a tube and the cells were collected. 600 μL of PBS was then added to the wells to wash the wells. The PBS in the wells was then transferred to the tube, and the remaining cells were collected in the tube. This tube was centrifuged at 4°C and 210 × g for 5 minutes. After centrifugation, the supernatant was removed, and the precipitate (cell pellet) was suspended (washed) in 1 mL of PBS and centrifuged under the same conditions as above. This procedure was repeated twice, and the supernatant was removed to obtain cells (cell pellet) cultured in Sample 1-containing medium.

[0056] The obtained cells (cell pellet) were analyzed for cell permeability in Sample 1 using a flow cytometer. The flow cytometer used was an On-Chip Flowcytometer (manufactured by On-Chip Biotechnologies Co., Ltd.). For this analysis, the obtained cell pellet was suspended in 50 μL of PBS, and 50 μL of the 2× sample buffer for the flow cytometer was added to this suspension to prepare a cell suspension for analysis.

[0057] Using the above flow cytometer, gating based on forward scatter (FSC) and side scatter (SSC) was performed to set a gate for the cell population to be analyzed, and the fluorescence intensity of the cell population within this gate was measured. Analysis was performed so that the cell population contained at least 10,000 cells. Fluorescence intensity was measured using the FL2 fluorescence detector of the above flow cytometer, which is capable of detecting the fluorescence wavelength of FAM (optimal detection wavelength: approximately 543 nm). The measurement results were analyzed using commercially available analysis software "FlowJo (registered trademark)" (TreeStar), and the mean fluorescent intensity (MFI) of the cell population to be measured was obtained.

[0058] (Example 2) The same procedure as in Example 1 was carried out, except that the above sample solution 1 was replaced with the above sample solution 2. (Example 3) The same procedure as in Example 1 was carried out, except that sample solution 1 was replaced with sample solution 3 prepared above. (Example 3') The same procedure as in Example 1 was carried out, except that sample solution 1 was replaced with sample solution 3' prepared above. (Example 4) The same procedure as in Example 1 was carried out, except that sample solution 1 was replaced with sample solution 4 prepared above. (Example 5) The same procedure as in Example 1 was carried out, except that Sample Solution 1 was a FAM solution diluted with DMSO. The concentration of this FAM solution was the same as that of Sample 1 solution (i.e., the FAM concentration in the culture medium in the well was 10 μM, and the DMSO concentration was 0.5%).

[0059] The results obtained for Examples 1 to 5 are shown in Table 3 and Figure 1. Figure 1 is a graph showing the MFI values ​​for each example.

[0060] [Table 3]

[0061] As shown in FIG. 1, Examples 1 to 4 all had higher MFI values ​​than Example 5. This indicates that Peptides 1 to 4 all have cell membrane permeability and can introduce foreign substances into cells. Furthermore, comparing Examples 1, 3, and 3', Example 1 had the highest MFI. This indicates that the amino acid sequence (SEQ ID NO: 1) in which the amino acid sequence WPC is added to the C-terminus of the amino acid sequence shown in SEQ ID NO: 4 has better cell membrane permeability than the peptide consisting of the amino acid sequence shown in SEQ ID NO: 4. Furthermore, comparing Examples 2 and 4, Example 2 had a significantly higher MFI. This indicates that the amino acid sequence (SEQ ID NO: 2) in which the amino acid sequence WPC is added to the C-terminus of the amino acid sequence shown in SEQ ID NO: 5 has better cell membrane permeability than the peptide consisting of the amino acid sequence shown in SEQ ID NO: 5. Furthermore, although detailed data are not shown, the inventors' studies have confirmed that foreign substances, whether they are fluorescent dyes, polypeptides, nucleic acids, or drugs, can be efficiently introduced from outside the cell through the cell membrane into the cytoplasm.

[0062] As is clear from the above, the construct for introducing foreign substances disclosed herein has excellent cell membrane permeability, and therefore it is possible to efficiently introduce the foreign substance of interest from the outside of a eukaryotic cell into at least the cytoplasm of the cell.

[0063] While specific examples of the technology disclosed herein have been described in detail above, these are merely examples and do not limit the scope of the claims. The technology described in the claims includes various modifications and alterations of the specific examples exemplified above. [Industrial Applicability]

[0064] The technology disclosed herein provides an artificially constructed construct for introducing a foreign substance of interest into the cytoplasm of a eukaryotic cell (particularly various animal cells, such as humans and other mammals, that do not have a cell wall). By utilizing such a construct, the foreign substance of interest can be effectively introduced into the target cell, and cells into which the foreign substance has been introduced, as well as biological tissues such as organs containing cells containing the foreign substance, can be obtained. Furthermore, by utilizing such a construct, therapeutic drugs for diseases can be provided. [Sequence List Free Text]

[0065] SEQ ID NOs: 1 to 9 Synthetic peptides

Claims

1. A method for introducing a foreign substance of interest into at least the cytoplasm of a eukaryotic cell in vitro from the outside of the cell, comprising: (1) the following amino acid sequence: KKRTLRKSNRKKRWPC (SEQ ID NO: 1); KKRTLRKKKRKKRWPC (SEQ ID NO: 2); a carrier peptide fragment consisting of any one of the foreign substance of interest bound to the N-terminal side and / or C-terminal side of the carrier peptide fragment; providing a construct for introducing an exogenous substance, (2) providing the construct for introducing a foreign substance into a sample containing a target eukaryotic cell; (3) incubating the sample to which the construct for introducing an exogenous substance has been supplied, thereby introducing the construct into eukaryotic cells in the sample; A method that encompasses

2. The method of claim 1, wherein the foreign substance is any organic compound selected from the group consisting of polypeptides, nucleic acids, dyes, and drugs.

3. The method of claim 1 or 2, wherein the foreign substance is located on the C-terminal side of the carrier peptide fragment.

4. The method according to claim 3, wherein the α-amino group of the lysine at the N-terminus of the carrier peptide fragment is acetylated.

5. The method according to any one of claims 1 to 4, wherein the eukaryotic cells into which the construct for introducing an exogenous substance is introduced are cells of a human or non-human mammal.

6. A construct for introducing a foreign substance, which is prepared for introducing a foreign substance of interest into at least the cytoplasm of a eukaryotic cell from the outside of the cell, The following amino acid sequence: KKRTLRKSNRKKRWPC (SEQ ID NO: 1); KKRTLRKKKRKKRWPC (SEQ ID NO: 2); a carrier peptide fragment consisting of any one of the foreign substance of interest bound to the N-terminal side and / or C-terminal side of the carrier peptide fragment; A construct for introducing an exogenous substance, comprising:

7. The construct according to claim 6, wherein the foreign substance is any organic compound selected from the group consisting of polypeptides, nucleic acids, dyes and drugs.

8. The construct of claim 6 or 7, wherein the foreign substance is located on the C-terminal side of the carrier peptide fragment.

9. The construct according to claim 8, wherein the α-amino group of the lysine on the N-terminal side of the carrier peptide fragment is acetylated.

Images